CRISPR Therapeutics (CRSP) PT Lowered to $60 at RBC Capital

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. CVS
7. SBUX
8. AXP
9. ZETA
10. TMUS

Go back to CRISPR Therapeutics (CRSP) PT Lowered to $60 at RBC Capital

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

August 5, 2024 4:01 PM EDT

-More than 35 authorized treatment centers (ATCs) activated globally for CASGEVY and approximately 20 patients have had cells collected across all regions as of mid-July-

-Clinical trials ongoing for next generation CAR T product candidates, CTX112 and CTX131 targeting CD19 and CD70 respectively, across multiple indications-

-Clinical trials opened for CTX112 in systemic lupus erythematosus (SLE) and for CTX131 in hematological malignancies-

-Clinical trials ongoing for in vivo gene editing product candidates, CTX310 and CTX320 targeting ANGPTL3 and LPA, respectively-

-Clinical... More